|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RBP5 |
Gene summary for RBP5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RBP5 | Gene ID | 83758 |
| Gene name | retinol binding protein 5 | |
| Gene Alias | CRBP-III | |
| Cytomap | 12p13.31 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | P82980 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 83758 | RBP5 | HCC1_Meng | Human | Liver | HCC | 7.13e-55 | 2.03e-01 | 0.0246 |
| 83758 | RBP5 | HCC1 | Human | Liver | HCC | 1.65e-19 | 5.39e+00 | 0.5336 |
| 83758 | RBP5 | HCC2 | Human | Liver | HCC | 2.35e-08 | 1.78e+00 | 0.5341 |
| 83758 | RBP5 | S014 | Human | Liver | HCC | 7.53e-18 | 8.47e-01 | 0.2254 |
| 83758 | RBP5 | S015 | Human | Liver | HCC | 7.69e-17 | 7.36e-01 | 0.2375 |
| 83758 | RBP5 | S016 | Human | Liver | HCC | 4.91e-21 | 8.00e-01 | 0.2243 |
| 83758 | RBP5 | S027 | Human | Liver | HCC | 3.25e-12 | 9.87e-01 | 0.2446 |
| 83758 | RBP5 | S028 | Human | Liver | HCC | 2.98e-29 | 1.29e+00 | 0.2503 |
| 83758 | RBP5 | S029 | Human | Liver | HCC | 2.58e-23 | 1.25e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RBP5 | SNV | Missense_Mutation | novel | c.160N>G | p.Thr54Ala | p.T54A | P82980 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RBP5 | insertion | Frame_Shift_Ins | novel | c.291_292insTG | p.Gln98CysfsTer24 | p.Q98Cfs*24 | P82980 | protein_coding | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | ||
| RBP5 | SNV | Missense_Mutation | novel | c.80N>A | p.Ser27Asn | p.S27N | P82980 | protein_coding | tolerated(0.99) | benign(0) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| RBP5 | SNV | Missense_Mutation | c.151A>G | p.Thr51Ala | p.T51A | P82980 | protein_coding | tolerated(0.29) | benign(0.038) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RBP5 | SNV | Missense_Mutation | c.215N>G | p.Glu72Gly | p.E72G | P82980 | protein_coding | deleterious(0.02) | benign(0.231) | TCGA-B5-A0JZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD | |
| RBP5 | SNV | Missense_Mutation | c.5N>T | p.Pro2Leu | p.P2L | P82980 | protein_coding | deleterious(0) | benign(0.263) | TCGA-D1-A16S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| RBP5 | SNV | Missense_Mutation | rs776452544 | c.184N>G | p.Thr62Ala | p.T62A | P82980 | protein_coding | tolerated(0.8) | benign(0.001) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| RBP5 | SNV | Missense_Mutation | c.32T>A | p.Phe11Tyr | p.F11Y | P82980 | protein_coding | deleterious(0.03) | possibly_damaging(0.481) | TCGA-DD-A1EI-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| RBP5 | SNV | Missense_Mutation | novel | c.159N>T | p.Arg53Ser | p.R53S | P82980 | protein_coding | deleterious(0.01) | benign(0.142) | TCGA-49-4487-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |